MS Research Studies

This study is being done to see how effective and tolerable ublituximab is when given to people who had been receiving different anti-CD20 therapy for relapsing multiple sclerosis. Ublituximab is approved by the US Food and Drug Administration (FDA) with the name BRIUMVI®, for adults with relapsing forms of multiple sclerosis.

The EFC17919/FREXALT trial is a Phase III clinical trial designed to assess the safety and efficacy of the investigational study drug against an existing treatment medication in RMS, teriflunomide.

The investigational study drug (frexalimab, which is administered intravenously) will be compared to teriflunomide (oral tablets). The purpose of this trial is to compare the investigational study drug to teriflunomide to see if the investigational study drug can possibly reduce the relapse frequency, and/or delay disease progression patients diagnosed with RMS.

Participants will be randomly selected to receive frexalimab or teriflunomide. The duration of study treatment will be between 20 to 40 months, depending on the moment when you start your participation. You may qualify for this study if you:

• Are between age 18 and 55
• Have a current diagnosis of relapsing forms of multiple sclerosis